A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
Stefan J. Hutten(The Netherlands Cancer Institute), Jos Jonkers(The Netherlands Cancer Institute)
Cited by 39
Related Papers
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
|Nature Structural & Molecular Biology|2010|1k
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
|Cell|2014|798
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
|Annals of Oncology|2018|424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271